{"protocolSection":{"identificationModule":{"nctId":"NCT06472739","orgStudyIdInfo":{"id":"GM-CSF for OM"},"organization":{"fullName":"Sun Yat-sen University","class":"OTHER"},"briefTitle":"The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy","officialTitle":"The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy: A Single-center, Phase II, Randomized Trial"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-09-15","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-08-15","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-11-15","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-08-30","studyFirstSubmitQcDate":"2024-06-23","studyFirstPostDateStruct":{"date":"2024-06-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-23","lastUpdatePostDateStruct":{"date":"2024-06-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Hai-Qiang Mai,MD,PhD","investigatorTitle":"Professor","investigatorAffiliation":"Sun Yat-sen University"},"leadSponsor":{"name":"Sun Yat-sen University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"To evaluate the efficacy of GM-CSF to preventing oral mucositis for patients with nasopharyngeal carcinoma receiving radiotherapy.","detailedDescription":"Patients of GM-CSF group receive GM-CSF washmouth four times a day during radiotherapy. Control arm receive conventioanl care during radiotherapy. Visual signs of radiation or chemotherapy-induced mucosal damage were independently assessed during the course of RT by a radiation oncologist or other trained study personnel. The incidence of severe oral mucositis, the severe oral mucositis last time, quality of life between the two arms would be calculated."},"conditionsModule":{"conditions":["GM-CSF"],"keywords":["Nasopharyngeal Carcinoma","GM-CSF","oral mucositis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":138,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"GM-CSF group","type":"EXPERIMENTAL","description":"Patients use GM-CSF mouthwash four times per day during radiotherpay.","interventionNames":["Drug: GM-CSF"]},{"label":"Convertional care group","type":"NO_INTERVENTION","description":"Patients receive convertional care during radiotherapy."}],"interventions":[{"type":"DRUG","name":"GM-CSF","description":"GM-CSF mouthwash four times per day at radiotherapy initiate, during the whole radiotherapy phase","armGroupLabels":["GM-CSF group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The incidence of severe oral mucositis(grade 3+)","description":"To evaluate the incidence of severe oral mucositis between the two arms.","timeFrame":"During radiotherapy, up to 1.5 months."}],"secondaryOutcomes":[{"measure":"Acute toxicities","description":"The incidence rates of acute toxicities during treatment, evaluted by CTCAE Version5.0.","timeFrame":"One month."},{"measure":"The last time of ≥3 grade oral mucositis","description":"The time from first observed ≥3 grade oral mucositis to first observed oral mucositis decrease to less than grade 3","timeFrame":"1 months after radiotherapy"},{"measure":"Daily questionaire of oral mucositis (OMDQ)","description":"Patients are required to finish daily questionaire of oral mucositis by visual signs","timeFrame":"1 months after radiotherapy"},{"measure":"Quality of life(QOL)","description":"QOL is calculated by QLQ-C30.","timeFrame":"1 months after radiotherapy"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* a. Patients with histologically confirmed non-keratinizing nasopharyngeal carcinoma (including differentiated type and undifferentiated type, world health organization \\[WHO\\] II or III).\n\n  b. Original clinical staged as II-IVa (according to the 8 th AJCC edition) c. Male or female who are not pregnant. d. No evidence of distant metastasis (M0). e. Age between 18-65 years. f. WBC≥4×109/L, PLT≥100×109/L, HGB≥90g/L. g. Normal liver function test: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) \\<1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤2.5×ULN, and bilirubin ≤ULN.\n\n  i. With normal renal function test (creatinine clearance rate≥60 ml/min or creatinine\\< 1.5×ULN.\n\n  j. The Eastern Cooperative Oncology Group (ECOG) Performance status less or equal to 1.\n\n  k. Patients must be informed of the investigational nature of this study and give written informed consent.\n\n  l. Patients receive induction chemotherapy plus concurrent chemoradiotherpy or concurrent chemoradiotherapy, or radiotherapy alone.\n\nExclusion Criteria:\n\n* Age \\<18 or \\>65years. c. With clinical stage of I or IVb (according to the 8 th AJCC edition). d. Patients with tumor recurrence or distant metastasis. e. Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer.\n\n  f. History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume).\n\n  g. Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.\n\n  h. Pregnancy or lactation (consider pregnancy test in women of child-bearing age and emphasize effective contraception during the treatment period).\n\n  i. Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, acute exacerbation of chronic obstructive pulmonary disease or other respiratory illness requiring admission to hospital, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \\>1.5×ULN), and mental disturbance.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Qiu Yan Chen, Dr","role":"CONTACT","phone":"020-87343380","email":"chenqy@sysucc.org.cn"}],"overallOfficials":[{"name":"Qiu Yan Chen, Dr","affiliation":"Sun Yat-sen University","role":"STUDY_CHAIR"}],"locations":[{"facility":"Sun Yat-sen University Cancer Center","status":"RECRUITING","city":"Guangzhou","state":"Guangdong","zip":"510060","country":"China","contacts":[{"name":"Qiu-Yan Chen, Dr.","role":"CONTACT","phone":"020-87343380","email":"chenqy@sysucc.org.cn"}],"geoPoint":{"lat":23.11667,"lon":113.25}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000002277","term":"Carcinoma"},{"id":"D000077274","term":"Nasopharyngeal Carcinoma"},{"id":"D000052016","term":"Mucositis"},{"id":"D000013280","term":"Stomatitis"}],"ancestors":[{"id":"D000009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000009303","term":"Nasopharyngeal Neoplasms"},{"id":"D000010610","term":"Pharyngeal Neoplasms"},{"id":"D000010039","term":"Otorhinolaryngologic Neoplasms"},{"id":"D000006258","term":"Head and Neck Neoplasms"},{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000009302","term":"Nasopharyngeal Diseases"},{"id":"D000010608","term":"Pharyngeal Diseases"},{"id":"D000009057","term":"Stomatognathic Diseases"},{"id":"D000010038","term":"Otorhinolaryngologic Diseases"},{"id":"D000005759","term":"Gastroenteritis"},{"id":"D000005767","term":"Gastrointestinal Diseases"},{"id":"D000004066","term":"Digestive System Diseases"},{"id":"D000009059","term":"Mouth Diseases"}],"browseLeaves":[{"id":"M5534","name":"Carcinoma","asFound":"Carcinoma","relevance":"HIGH"},{"id":"M26955","name":"Mucositis","asFound":"Mucositis","relevance":"HIGH"},{"id":"M16070","name":"Stomatitis","asFound":"Oral Mucositis","relevance":"HIGH"},{"id":"M1730","name":"Nasopharyngeal Carcinoma","asFound":"Nasopharyngeal Carcinoma","relevance":"HIGH"},{"id":"M12320","name":"Neoplasms, Glandular and Epithelial","relevance":"LOW"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M12254","name":"Nasopharyngeal Neoplasms","relevance":"LOW"},{"id":"M13517","name":"Pharyngeal Neoplasms","relevance":"LOW"},{"id":"M12962","name":"Otorhinolaryngologic Neoplasms","relevance":"LOW"},{"id":"M9348","name":"Head and Neck Neoplasms","relevance":"LOW"},{"id":"M12253","name":"Nasopharyngeal Diseases","relevance":"LOW"},{"id":"M13515","name":"Pharyngeal Diseases","relevance":"LOW"},{"id":"M12017","name":"Stomatognathic Diseases","relevance":"LOW"},{"id":"M12961","name":"Otorhinolaryngologic Diseases","relevance":"LOW"},{"id":"M8875","name":"Gastroenteritis","relevance":"LOW"},{"id":"M8883","name":"Gastrointestinal Diseases","relevance":"LOW"},{"id":"M7255","name":"Digestive System Diseases","relevance":"LOW"},{"id":"M12019","name":"Mouth Diseases","relevance":"LOW"},{"id":"T4047","name":"Nasopharyngeal Carcinoma","asFound":"Nasopharyngeal Carcinoma","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC06","name":"Digestive System Diseases"},{"abbrev":"BC07","name":"Mouth and Tooth Diseases"},{"abbrev":"BC09","name":"Ear, Nose, and Throat Diseases"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}